

## Treatment of Metastatic Renal Cell Carcinoma With Autologous T-Lymphocytes Genetically Retargeted Against Carbonic Anhydrase IX: First Clinical Experience

**TO THE EDITOR:** Adoptive transfer of autologous T-lymphocytes that are gene transduced to express antigen-specific receptors represents an experimental therapy to provide tumor-specific immunity to cancer patients. We studied safety and the proof of this concept in patients with metastatic renal cell carcinoma (RCC), and have encountered toxicity that is likely to be antigen specific.

We have constructed a single-chain antibody-type (scFv) –receptor based on murine monoclonal antibody (mAb) G250.<sup>1</sup> This mAb recognizes an epitope on carboxy-anhydrase-IX (CAIX), which is frequently overexpressed on clear cell RCC. Following retroviral introduction of the *scFv(G250)* transgene into primary human T-cells, the scFv(G250) receptor is expressed on the surface of these cells, which enables them to recognize CAIX and to exert antigen-specific effector functions, such as cytokine production after exposure to CAIX and the killing of CAIX<sup>+</sup> RCC cell lines.<sup>2,3</sup>

We treated patients with scFv(G250)-transduced T-cells in an inpatient dose-escalation scheme of intravenous (IV) doses of  $2 \times 10^7$  cells at day 1;  $2 \times 10^8$  cells at day 2;  $2 \times 10^9$  cells at days 3 through 5 (treatment cycle 1); and  $2 \times 10^9$  cells at days 17 to 19 (treatment cycle 2), in combination with human recombinant interleukin-2 (IL-2; Chiron Corporation, Amsterdam, the Netherlands), subcutaneously,  $5 \times 10^5$  U/m<sup>2</sup> twice daily administered at days 1 to 10 and days 17 to 26. This protocol was approved by the governmental regulatory authorities and the institutional medical ethical review board. Adaptations to this protocol were implemented only after approval by these boards. Written informed consent was obtained from all patients.

In this letter, we report on the clinical experiences of the first three patients. The patients had CAIX<sup>+</sup> metastatic clear cell RCC, had undergone tumor nephrectomy, and had progressive disease after 6 to 17 months of interferon alfa (IFN- $\alpha$ ) treatment. From all, we successfully generated functional scFv(G250)<sup>+</sup> T-cells *ex vivo* (Table 1). Infusions of these gene-modified T-cells were initially well-tolerated. However, after four to five infusions, liver enzyme disturbances reaching National Cancer Institute Common Toxicity Criteria grades 2 to 4 developed. These toxicities necessitated the cessation of treatment in patient 1 and patient 3, corticosteroid treatment in patient 1, and reduction of the maximal T-cell dose to  $2 \times 10^8$  T-cells in patient 2 and patient 3. After treatment, patients showed progressive disease between 36 and 106 days. In order to elucidate the underlying mechanisms accounting for the liver toxicity, a liver biopsy was performed on patient 1, showing a discrete cholangitis with T-cell infiltration around the bile ducts, and CAIX expression on the bile duct epithelial cells. Although technical limitations prohibited direct identification of

scFv(G250)<sup>+</sup> T-cells in these sections, these findings strongly suggest that the liver toxicity is caused by a specific attack of the scFv(G250)<sup>+</sup> T-cells against the CAIX<sup>+</sup> bile duct epithelial cells.

We transiently detected both scFv(G250)<sup>+</sup> T-cells and scFv(G250) DNA copies in the circulation of all three patients from day 3 of treatment onward, using flow cytometry and quantitative real-time polymerase chain reaction (PCR). The time period during which the transduced cells were detected in the circulation depended on the method used, that is, up to 32 days by flow cytometry and up to 53 days by PCR<sup>4</sup> (Table 1).

Before treatment, peripheral blood mononuclear cells did not show scFv(G250)-mediated functions, that is, specific cytolysis of CAIX<sup>+</sup> target cells and production of IFN- $\gamma$  on stimulation with such cells. After infusions of scFv(G250)-transduced T cells, these activities became detectable in all three patients (Table 1).

All three patients developed low levels of anti-scFv(G250) antibodies between 37 and 100 days after the start of T-cell therapy, which were directed against the G250 idiotype (id). Remarkably, these responses were less frequent in RCC patients treated with weekly IV infusions of 50 mg chimeric G250 mAb (ie, in 6% to 30% of patients),<sup>5,6</sup> indicating that the expression of scFv(G250) on the cell membrane of T-cells elicits a relatively efficient immune response against the murine G250-id. Such response may hamper the effective clinical use of murine-human chimeric receptors, and may require construction of receptors from completely human mAbs.

In summary, our data show clear *in vivo* reactivity of autologous T-cells that have been genetically retargeted using a single-chain antibody-type receptor. The observed liver toxicity is most likely due to the reactivity of transduced T-cells against the target antigen expressed on normal tissue, that is, the epithelial cells lining the bile ducts, and thereby hinders administration of T-cells in numbers that can be expected to yield antitumor activity. We consider our observations, together with those from T-cell therapies directed against self-antigens,<sup>7,8</sup> relevant for other studies involving T-cell retargeting for therapeutic purposes. Ideally, the target antigens for such studies should be carefully chosen, so as to be expressed only by malignant cells and not by normal cells.

Alternatively, strategies need to be developed to attenuate activity of retargeted T-cells against normal tissues expressing target antigen to circumvent the observed adverse events.

In order to prevent liver toxicity in future patients, we have modified our clinical protocol into a conventional phase I study, and have included an infusion of 5 mg cG250 antibody 3 days before the first infusion of gene-modified T-cells. The rationale of this amended protocol is that repeated administration of cG250 has not only been shown to be clinically safe and well-tolerated by more than 200 patients,<sup>9</sup> but more importantly, cG250 localizes to RCC metastasis but not to the liver, after having saturated uptake by liver tissue (but not RCC metastasis) by a single low dose of cG250.<sup>6,10,11</sup> By pretreating patients with a single, low dose of cG250, we aim to protect the bile duct epithelium from the damaging effects exerted by scFv(G250)<sup>+</sup>

**Table 1.** Characteristics of Preinfusion scFv(G250)-Transduced T-Cells and of Peripheral Blood Following Immunogene Therapy

Parameter	Patient 1	Patient 2*	Patient 3*
<b>Preinfusion characteristics of scFv(G250)-transduced T-cells</b>			
Cell and DNA copy counts			
No. of infusions	4†	5/3‡	4†
Total No. of T-cells ( $\times 10^9$ )	3.99	0.8/0.59	0.60
Mean % scFv(G250) <sup>+</sup> T-cells	53	52/76	63
Total No. of scFv(G250) <sup>+</sup> T-cells ( $\times 10^9$ )	2.13	0.43/0.42	0.38
Mean No. of scFv(G250) DNA copies per scFv(G250) <sup>+</sup> T-cell	2.3	4.5/6.8	2.8
scFv(G250)-mediated functions			
CAIX-specific cytotoxicity (LU <sub>20</sub> )§			
LU <sub>20</sub> /10 <sup>6</sup> scFv(G250) <sup>+</sup> T-cells	372	104/82	88
Total LU <sub>20</sub>	792, 204	78, 774	33, 274
CAIX-specific IFN- $\gamma$ production, ng per 10 <sup>6</sup> scFv(G250) <sup>+</sup> T-cells per 24h	33	33/24	28
<b>Characteristics of peripheral blood samples during immunogene therapy</b>			
Circulating scFv(G250) <sup>+</sup> T-lymphocytes			
Peak, day	7	10/21	6
Peak level, cells/ $\mu$ l	5.3	2.7/1.6	0.8
Period during which cells detectable	3-23	3-32	3-7
Circulating scFv(G250) DNA copies			
Peak, day	tfd	17/19	8
Peak level, cells/ $\mu$ l	tfd	7.1/5.2	5.3
Period during which DNA detectable	tfd	tfd-53	3-32
Human anti-scFv(G250) antibodies			
Day of first appearance	37	100	79
Peak, day	57¶	100¶	79
Peak level, ng/ml	706	190	292
ScFv(G250)-mediated functions in vitro			
CAIX-specific cytotoxicity			
Peak, day	8	8/22	5
Peak level, LU <sub>20</sub> /10 <sup>6</sup> PBMC	16	29/44	26
CAIX-specific IFN- $\gamma$ production			
Peak, day	8	8/22	5
Peak level, ng/ml per 10 <sup>6</sup> PBMC per 24h	9	25/32	37

Abbreviations: scFv, single-chain antibody type; LU, lytic unit; CAIX, carboxy-anhydrase IX; IFN, interferon; h, hour; PBMC, peripheral blood mononuclear cells; tfd, too few data points to allow data assessment.

\*T-cell dose reduced to a maximum of  $2 \times 10^8$  T-cells.

†Treatment cycle 1 only.

‡Treatment cycle 1/treatment cycle 2.

§One LU<sub>20</sub> is defined as the number of effector T-cells required to lyse 20% of 2,500 CAIX target cells in a 4 h <sup>51</sup>Cr release assay.

||Day(s) after start of treatment (day 1 = day of first infusion).

¶Last day of observation.

T-cells. The Dutch regulatory authorities have approved this amended protocol and accrual of patients is currently ongoing.

*Cor H.J. Lamers, Stefan Sleijfer, Arnold G. Vulto, Wim H.J. Kruit, Mike Kliffen, Reno Debets, Jan W. Gratama, and Gerrit Stoter*

Departments of Medical Oncology, Pharmacy, and Pathology, Erasmus University Medical Center—Daniel den Hoed Cancer Center, Rotterdam, the Netherlands

*Egbert Oosterwijk*

Department of Experimental Urology, University Medical Center, Nijmegen, the Netherlands

## REFERENCES

- Weijtens MEM, Willemsen RA, Valerio D, et al: Single chain Ig/gamma gene-redirceted human T lymphocytes produce cytokines, specifically lyse tumor cells, and recycle lytic capacity. *J Immunol* 157:836-843, 1996
- Lamers CH, Willemsen RA, Luiders BA, et al: Protocol for gene transduction and expansion of human T lymphocytes for clinical immunogene therapy of cancer. *Cancer Gene Ther* 9:613-623, 2002

- Lamers CHJ, Willemsen RA, van Elzakker P, et al: Phoenix-ampho outperforms PG13 as retroviral packaging cells to transduce human T cells with tumor-specific receptors: Implications for clinical immunogene therapy of cancer. *Cancer Gene Ther* 10.1038/sj.cgt.7700916 (Epub ahead of print on November 11, 2005)

- Lamers CHJ, Gratama JW, Pouw N, et al: Parallel detection of transduced T lymphocytes following immuno-gene therapy of renal cell cancer by flow cytometry and real-time PCR: Implications for loss of transgene expression. *Hum Gene Ther* 16:1452-1462, 2005

- Divigi CR, O'Donoghue JA, Welt S, et al: Phase I clinical trial with fractionated radioimmunotherapy using 131I-labeled chimeric G250 in metastatic renal cancer. *J Nucl Med* 45:1412-1421, 2004

- Brouwers AH, Mulders PF, de Mulder PH, et al: Lack of efficacy of two consecutive treatments of radioimmunotherapy with 131I-cG250 in patients with metastasized clear cell renal cell carcinoma. *J Clin Oncol* 23:6540-6548, 2005

- Rosenberg SA, Dudley ME: Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes. *Proc Natl Acad Sci U S A* 101:14639-14645, 2004 (suppl 2)

- Dudley ME, Wunderlich JR, Yang JC, et al: Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. *J Clin Oncol* 23:2346-2357, 2005

## Correspondence

9. Bleumer I, Knuth A, Oosterwijk E, et al: A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients. *Br J Cancer* 90:985-990, 2004

10. Steffens MG, Boerman OC, Oyen WJ, et al: Intratumoral distribution of two consecutive injections of chimeric antibody G250 in primary renal cell carcinoma: Implications for fractionated dose radioimmunotherapy. *Cancer Res* 59:1615-1619, 1999

11. Steffens MG, Oosterwijk-Wakka JC, Zegwaard-Hagemeier NE, et al: Immunohistochemical analysis of tumor antigen saturation following injection of monoclonal antibody G250. *Anticancer Res* 19:1197-1200, 1999

DOI: 10.1200/JCO.2006.05.9964

---

### Acknowledgment

This letter was supported by the Dutch Cancer Foundation (Grant No. DDHK99-1865), European Commission Grant No.

QLK3-1999-01262, and the Cancer Research Institute, New York, NY (clinical investigation grant "Immunogene therapy of metastatic renal cell cancer patients"). This letter was presented in part at the European Society of Gene Therapy 2004 meeting in Tampere, Finland and at the International Society for Cellular Therapy 2005 meeting in Vancouver, British Columbia, Canada.

### Authors' Disclosures of Potential Conflicts of Interest

The authors indicated no potential conflicts of interest.

# JOURNAL OF CLINICAL ONCOLOGY

Official Journal of the American Society of Clinical Oncology

Vol 24, No 13

C O N T E N T S

May 1, 2006

## Presidential Address

### ASCO in the 21st Century: Challenges and Opportunities—ASCO Presidential Address 2005

David H. Johnson ..... 1967

## Editorials

### Inherited Genetic Markers and Cancer Outcomes: Personalized Medicine in the Postgenome Era

Timothy R. Rebbeck (see article on page 1982) ..... 1972

### Exploring Dose-Intensity: Carefully Comparing High-Dose With Low-Dose External-Beam Radiotherapy for Prostate Cancer

Howard M. Sandler (see article on page 1990) ..... 1975

### ■ Sentinel Lymph Node Histopathology in Breast Cancer: Minimal Disease Versus Artifact

Beverley A. Carter and David L. Page (see article on page 2013) ..... 1978

### Reponses to Topoisomerase-I Inhibitors in Extensive Small-Cell Lung Cancer: Chance or Chromosomes?

Michael C. Perry (see articles on pages 2038 and 2044) ..... 1980

## Original Reports

### GENITOURINARY CANCER

### Impact of *IGF-I* and *CYP19* Gene Polymorphisms on the Survival of Patients With Metastatic Prostate Cancer

Norihiko Tsuchiya, Lizhong Wang, Hiroyoshi Suzuki, Takehiko Segawa, Hisami Fukuda, Shintaro Narita, Masaki Shimbo, Toshiyuki Kamoto, Kenji Mitsumori, Tomohiko Ichikawa, Osamu Ogawa, Akira Nakamura, and Tomonori Habuchi (see editorial on page 1972) ..... 1982

### Dose-Response in Radiotherapy for Localized Prostate Cancer: Results of the Dutch Multicenter Randomized Phase III Trial Comparing 68 Gy of Radiotherapy With 78 Gy

Stephanie T.H. Peeters, Wilma D. Heemsbergen, Peter C.M. Koper, Wim L.J. van Putten, Annerie Slot, Michel F.H. Dielwart, Johannes M.G. Bonfrer, Luca Incrocci, and Joos V. Lebesque (see editorial on page 1975) ..... 1990

### Impact of Immune Parameters on Long-Term Survival in Metastatic Renal Cell Carcinoma

Frede Donskov and Hans von der Maase ..... 1997

(continued on following page)

*Journal of Clinical Oncology* (ISSN 0732-183X) is published 36 times a year, three times monthly, by American Society of Clinical Oncology, 1900 Duke St, Suite 200, Alexandria, VA 22314. Periodicals postage is paid at Alexandria, VA, and at additional mailing offices. Publication Mail Agreement Number 863289.

Editorial correspondence should be addressed to Daniel G. Haller, MD, *Journal of Clinical Oncology*, 330 John Carlyle St, Suite 300, Alexandria, VA 22314. Telephone: (703) 797-1900; Fax: (703) 684-8720. E-mail: jco@asco.org. Internet: www.jco.org.

**POSTMASTER:** ASCO members send change of address to American Society of Clinical Oncology, 1900 Duke St, Suite 200, Alexandria, VA 22314. Nonmembers send change of address to *Journal of Clinical Oncology* Customer Service, 330 John Carlyle St, Suite 300, Alexandria, VA 22314.

2006 annual subscription rates, effective September 1, 2005: United States and possessions: individual, \$435; single issue, \$35. International: individual, \$605; single issue, \$45. Institutions: Tier 1: \$615 US, \$870 Int'l; Tier 2: \$715 US, \$970 Int'l; Tier 3: \$1,035 US, \$1,290 Int'l; Tier 4: \$1,140 US, \$1,395 Int'l; Tier 5: contact *JCO* for a quote. See <http://www.jco.org/subscriptions/tieredpricing.shtml> for descriptions of each tier. Student and resident: United States and possessions: \$215; all other countries, \$300. To receive student/resident rate, orders must be accompanied by name of affiliated institution, date of term, and the signature of program/residency coordinator on institution letterhead.

**Mortality After Major Surgery for Urologic Cancers in Specialized Urology Hospitals: Are They Any Better?**

Badrinath R. Konety, Veerasathpurush Allareddy, Sanjukta Modak, and Brian Smith ..... 2006

**BREAST CANCER**

**Axillary Sentinel Lymph Nodes Can Be Falsely Positive Due to Iatrogenic Displacement and Transport of Benign Epithelial Cells in Patients With Breast Carcinoma**

Ira J. Bleiweiss, Chandandeep S. Nagi, and Shabnam Jaffer (see editorial on page 1978) ..... 2013

**Sequential Preoperative or Postoperative Docetaxel Added to Preoperative Doxorubicin Plus Cyclophosphamide for Operable Breast Cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27**

Harry D. Bear, Stewart Anderson, Roy E. Smith, Charles E. Geyer Jr, Eleftherios P. Mamounas, Bernard Fisher, Ann M. Brown, Andre Robidoux, Richard Margolese, Morton S. Kahlenberg, Soonmyung Paik, Atilla Soran, D. Lawrence Wickerham, and Norman Wolmark ..... 2019

**Prognosis After Ipsilateral Breast Tumor Recurrence and Locoregional Recurrences in Five National Surgical Adjuvant Breast and Bowel Project Node-Positive Adjuvant Breast Cancer Trials**

Irene L. Wapnir, Stewart J. Anderson, Eleftherios P. Mamounas, Charles E. Geyer Jr, Jong-Hyeon Jeong, Elizabeth Tan-Chiu, Bernard Fisher, and Norman Wolmark ..... 2028

**LUNG CANCER**

**Randomized Phase III Trial Comparing Irinotecan/Cisplatin With Etoposide/Cisplatin in Patients With Previously Untreated Extensive-Stage Disease Small-Cell Lung Cancer**

Nasser Hanna, Paul A. Bunn Jr, Corey Langer, Lawrence Einhorn, Troy Guthrie Jr, Thaddeus Beck, Rafat Ansari, Peter Ellis, Michael Byrne, Mark Morrison, Subramanian Hariharan, Benjamin Wang, and Alan Sandler (see editorial on page 1980) ..... 2038

**Open-Label, Multicenter, Randomized, Phase III Study Comparing Oral Topotecan/Cisplatin Versus Etoposide/Cisplatin As Treatment for Chemotherapy-Naive Patients With Extensive-Disease Small-Cell Lung Cancer**

John R. Eckardt, Joachim von Pawel, Zsolt Papai, Antoaneta Tomova, Valentina Tzekova, Theresa E. Crofts, Sarah Brannon, Paul Wissel, and Graham Ross (see editorial on page 1980) ..... 2044

**CLINICAL TRIALS**

**Phase I, Pharmacokinetic, and Pharmacodynamic Study of Intravenously Administered Ad5CMV-p53, an Adenoviral Vector Containing the Wild-Type p53 Gene, in Patients With Advanced Cancer**

Anthony W. Tolcher, Desiree Hao, Johann de Bono, Alex Miller, Amita Patnaik, Lisa A. Hammond, Leslie Smetzer, Jill Van Wart Hood, James Merritt, Eric K. Rowinsky, Chris Takimoto, Dan Von Hoff, and S. Gail Eckhardt ..... 2052

**GASTROINTESTINAL CANCER**

**Oral Uracil and Tegafur Plus Leucovorin Compared With Intravenous Fluorouracil and Leucovorin in Stage II and III Carcinoma of the Colon: Results From National Surgical Adjuvant Breast and Bowel Project Protocol C-06**

Barry C. Lembersky, H. Samuel Wieand, Nicholas J. Petrelli, Michael J. O'Connell, Linda H. Colangelo, Roy E. Smith, Thomas E. Seay, Jeffrey K. Giguere, M. Ernest Marshall, Andrew D. Jacobs, Lauren K. Colman, Atilla Soran, Greg Yothers, and Norman Wolmark ..... 2059

**Chemotherapy Regimen Predicts Steatohepatitis and an Increase in 90-Day Mortality After Surgery for Hepatic Colorectal Metastases**

Jean-Nicolas Vauthey, Timothy M. Pawlik, Dario Ribero, Tsung-Teh Wu, Daria Zorzi, Paulo M. Hoff, Henry Q. Xiong, Cathy Eng, Gregory Y. Lauwers, Mari Mino-Kenudson, Mauro Risio, Andrea Muratore, Lorenzo Capussotti, Steven A. Curley, and Eddie K. Abdalla ..... 2065

(continued on following page)

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.